Just as Artificial intelligence (AI) is in many everyday technologies, AI is becoming an integral part to many aspects of drug discovery, development and patient care. Learn how AI is advancing the biopharma industry to bring safer and better drugs to patients.
Irene Pak is the head of AI Data and Technology Lab at BMS. In her current role, she is responsible for driving AI transformation across the enterprise.
Irene joined Bristol-Myers Squibb in 2015 as an IT Business Partner and developed numerous fit-for-purpose capabilities to enable Translational Medicine colleagues to quickly access and interpret heterogeneous clinical biomarker data and adverse events in early and late clinical programs. In 2017, she took on the role as the R&D Data Architect to drive meaningful data and information architecture in R&D, leading to better insights and more effective utilization of our data assets. Prior to joining BMS, Irene spent many years at Merck playing various roles in small molecule and biologics development programs, as well as delivering innovative R&D solutions using machine learning and visualization technologies. Irene holds a bachelor's degree in Computer Science from Princeton University and a master's degree in Operations Research and Biomedical Engineering from Columbia University.
Today, she will be presenting how AI is advancing the biopharma industry for patients across the world.
Brought to you by:
This event was held online. The recording is available for WITI Members.